Alirocumab addition to statins fails to improve endothelial function in acute MI patients: PACMAN-AMI trial substudy Medha Baranwal15 May 2024 10:00 AM ISTSwitzerland: In a significant development in cardiovascular medicine, findings from a substudy of the PACMAN-AMI randomized clinical trial shed light...
Lipoprotein (a) assay methods similarly predict MACE reduction with PCSK9 inhibitor Alirocumab: Study Medha Baranwal22 March 2024 8:30 PM ISTUSA: A recent comparison of changes in lipoprotein(a) mass and molar concentrations found that each essay method is similarly predictive of major...
Alirocumab and high-intensity statin combo may significantly regress coronary plaque burden in familial hypercholesterolemia Medha Baranwal10 Feb 2024 10:00 AM ISTSpain: Alirocumab-combined with high-intensity statin therapy-led to a greater coronary plaque burden (PB) regression in patients with familial...
Alirocumab an efficacious lipid-lowering therapy for children with heterozygous familial hypercholesterolemia: JAMA Medha Baranwal9 Feb 2024 10:30 AM ISTUSA: A randomized clinical trial of 153 patients revealed that alirocumab may be an effective adjunct lipid-lowering therapy (LLT) for pediatric...
Triple regression in MI patients with alirocumab linked to low LDL C and MACE Aditi15 Nov 2023 10:00 PM ISTTriple regression is characterized by reduced atheroma volume, lower lipid content, and thicker fibrous caps. Researchers have found in a new study...
PCSK9 inhibitors act through plaque stabilisation not by improving coronary physiology: PACMAN-AMI trial Medha Baranwal13 July 2023 10:15 AM ISTSwitzerland: Acute myocardial infarction (AMI) patients treated with alirocumab had a significant regression in angiographic diameter stenosis (DS%)....
Alirocumab reduces plaque load in patients with familial hypercholesterolemia Jacinthlyn Sylvia11 April 2023 10:00 AM ISTA new study published in Circulation, shows that in individuals with familial hypercholesterolemia who did not have clinical cardiac disease, a year...
Adding lipid-lowering therapies to statin therapy help to achieve low-LDL cholesterol goals Dr. Kamal Kant Kohli30 Dec 2022 10:15 AM ISTUSA: When combined with maximally tolerated statins to reduce LDL-C, non-high-density lipoprotein cholesterol, and apolipoprotein B levels and make it...
Early addition of PCSK9 inhibitors to statins significantly reduce LDL-C in STEMI patients undergoing PCI Jacinthlyn Sylvia23 Sept 2022 11:00 AM ISTCanada: Early supplementation of PCSK9 inhibitor along with high-intensity statin further decreases LDL cholesterol (by 22%) in patients undergoing...
Alirocumab addition to statins significantly regresses plaque in non infarct-related coronary arteries MD Bureau22 April 2022 9:00 AM ISTStatins have been shown to reduce cardiovascular adverse events in patients with atherosclerotic disease. In a recent study, researchers have reported...
Alirocumab benefits CAD patients only if lipoprotein (a) levels elevated: Study Dr. Shravani Dali19 Aug 2021 9:15 AM ISTIn patients with recent acute coronary syndromes PCSK9 inhibitor alirocumab provides substantial clinical benefit only when lipoprotein(a)...
FDA approves alirocumab for homozygous FH as addon therapy Dr. Kamal Kant Kohli2 April 2021 6:50 AM ISTThe US food and drug administration (FDA) has expanded approval of Praluent (alirocumab) injection for adult patients with homozygous familial...
